Article
Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 1 Oct 2014
Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Onishi Yasuharu, Kamei Hideya, Hayashi Kazuhiko, Ogura Yasuhiro, Hirooka Yoshiki, Goto Hidemi
Abstract excerpt
The combination of nucleos(t)ide analogues (NAs) and hepatitis B immune globulin has been established as safe and effective prophylaxis against hepatitis B virus (HBV) reactivation after liver transplantation (LT). However, the essential weak point of this regimen is its high cost. The hepatitis B (HB) vaccine is an attractive alternative that costs less, and it enables some patients to have sufficiently high...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.